Clinical trials for Chronic myeloid leukemia (CML)
24 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
Partie B (Mutation T315I)
Required disease stage
Chronic phase
Required genetic anomalies
T315I
1 recruiting site
Ascentage Pharma Group Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
Partie A (Non-T315I)
Required disease stage
Chronic phase
Required number of previous lines of therapy
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Ascentage Pharma Group Inc.
Phase 2
Chronic myeloid leukemia (CML)
#NCT02889003
Required number of previous lines of therapy
1
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
BCR-ABL
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
Hôpital de Versailles
Phase 2
Chronic myeloid leukemia (CML)
#NCT06514534
#2024-516049-38-00
Required disease stage
Chronic phase
Accelerated phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Excluded previous treatments
Systemic Treatment-Naive
Allosteric inhibitor
7 recruiting sites
Novartis
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT04835584
LMC en phase accélérée (Phase 2 Bras C)
Required disease stage
Accelerated phase
Required genetic anomalies
BCR-ABL
Ph+ (Philadelphia chromosome positive)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
TP53
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT04835584
LMC Phase Chronique (phase 1b et phase 2 Bras A et B)
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Ph+ (Philadelphia chromosome positive)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
TP53
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT06163430
#2023-507677-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1
Chronic myeloid leukemia (CML)
#NCT05304377
#2023-503335-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Enliven Therapeutics
Phase 1
1 recruiting site